ILIT Administration for Trust Attorneys: The Policy Disposition Question

How ILITs Arrive at the Disposition Question

Irrevocable life insurance trusts were drafted in enormous numbers between the late 1980s and 2017, mostly to keep death benefits outside taxable estates when the federal exemption was a fraction of today’s figure. Three forces now push their policies toward disposition. Purpose decay: with the federal exemption above $13 million per individual, many insureds no longer face the estate tax the trust was built to fund — though state estate and inheritance taxes, and the risk of a lower future exemption, keep the analysis honest. Policy decay: universal life contracts illustrated at 1990s crediting rates have underperformed for decades; cost-of-insurance charges rise with age, cash values erode, and in-force illustrations show policies dying before insureds do unless premiums increase sharply. Funding decay: grantors age, gift fatigue sets in, annual exclusion gifts stop, and the trustee is left holding a policy with no premium source.

When these forces converge, the trustee faces a genuine investment decision among alternatives with radically different values. The legal predicate is a century old — Grigsby v. Russell established a policy as transferable property in 1911 — and the modern market is institutional: licensed providers backed by pension funds and asset managers, pricing policies via discounted cash flow on independent life expectancy reports. The GAO documented that sellers received several multiples of cash surrender value. Trust counsel who want the transaction fundamentals before the fiduciary overlay can start with what a life settlement is.

The Trustee’s Duty: Prudent Investor Rule Applied to a Policy

Under the Uniform Prudent Investor Act as adopted across the states, a trustee must manage trust assets as a prudent investor would — monitoring performance, considering the asset’s role in the portfolio, and acting when circumstances require. Applied to an ILIT’s single dominant asset, the duty has concrete content:

• Monitor. Obtain in-force illustrations periodically (annually for stressed policies), at both current funding and guaranteed assumptions, and track the crossover point where the policy fails.
• Evaluate. When funding falters or purpose changes, assemble the option set — maintain, restructure, reduce, exchange, surrender, sell — and compare values, not vibes.
• Act. Choose and implement the option a prudent fiduciary would select for these beneficiaries, and document why.

The exposure runs both directions, which is what makes the question genuinely hard. A trustee who lets a marketable policy lapse — or surrenders it for a fraction of the offers a market test would have produced — faces beneficiary claims with clean damages: the foregone settlement value. A trustee who sells a policy that beneficiaries expected to pay ten times the sale price at death faces the mirror-image claim, especially if the insured dies shortly after closing. Neither claim survives a documented process: a market test through licensed intermediaries, a written comparison of alternatives, beneficiary notice, and a reasoned decision memo. Trust counsel’s job is to force that process into existence. The trustee-facing version of this analysis is developed in the ILIT trustee duties guide and life settlements for trustees.

Authority: Reading the Instrument Before Reading the Market

Before any market activity, counsel should resolve whether this trustee may sell this policy on these terms. The checklist:

• Powers of sale. Most instruments grant general powers to sell trust property, which cover a policy sale. Older ILITs occasionally enumerate powers narrowly or speak only of holding and maintaining insurance; where the language is doubtful, consider a nonjudicial settlement agreement, judicial instruction, or decanting to a modern instrument before proceeding.
• Directed and co-trustee structures. Confirm who actually holds the disposition power — a corporate trustee may be directed by an insurance protector or investment adviser, and family co-trustees may need to act jointly.
• Conflicted trustees. A trustee-beneficiary deciding between a lapse (nothing for anyone), a sale (cash to the trust now), and maintenance (benefit later, possibly skewed among beneficiaries) is making a decision that affects their own interest. Disclosure, beneficiary consent, or an independent special trustee for the transaction cleans the posture.
• Beneficiary involvement. Notice is cheap insurance; written consent or a settlement agreement is stronger. Beneficiaries who signed off on a documented market test rarely become plaintiffs.
• Insurable interest and waiting periods. State settlement statutes, generally following the NAIC Model Act, impose two-to-five-year waiting periods on policy sales with exceptions for events like divorce, retirement, or illness; confirm the policy’s age and the trust’s acquisition history — and screen hard for any STOLI taint in the origination, which is disqualifying.

Counsel should also confirm the state’s licensing scheme for the intermediaries: in New Jersey, brokers and providers must be licensed under the Viatical Settlements Act, verifiable through the Department of Banking and Insurance.

Trustee Action on a Stressed Policy	Value to Trust	Fiduciary Risk Profile	Required Documentation
Quiet lapse	$0	Highest — clean damages if policy was marketable	Market screen showing no value; memo explaining decision
Surrender	Cash surrender value (often depleted)	High if market untested — foregone-offer claims	Market test results; comparison memo
Restructure / reduce face	Partial coverage retained	Moderate — beneficiaries get less at death	In-force illustrations; beneficiary notice
Maintain with new funding	Full death benefit preserved	Low if funding realistic; high if policy fails anyway	Funding plan; annual illustration monitoring
1035 exchange	Tax-deferred repositioning	Moderate — new product suitability	Comparison illustrations; insurability evidence
Life settlement	Typically 10–35% of face; often 4–8× CSV	Moderate — mirror-image claims if insured dies soon after	Competitive offers; alternatives memo; beneficiary notice/consent; tax projection

The Option Set: What the Trustee’s Memo Must Compare

A defensible disposition memo prices every realistic alternative, because the settlement only wins when it actually wins. The standard set:

• Maintain as-is. Requires a premium source — renewed grantor gifts, beneficiary contributions, trust assets, or a split-dollar arrangement. Right answer when the death benefit still serves the beneficiaries and funding is realistic.
• Restructure. Reduce face amount to a sustainable premium; drop riders; use existing cash value to carry a smaller benefit. Preserves partial coverage without new money.
• 1035 exchange. Tax-deferred exchange into a better-priced or guaranteed product — viable mainly for insurable insureds, which the stressed-ILIT fact pattern often lacks.
• Surrender. Realizes cash surrender value, often modest in decayed UL contracts. Correct for policies with no secondary-market value.
• Lapse. Realizes nothing. Defensible only after a market screen shows no value, and the memo should say so explicitly.
• Life settlement. A market test through a licensed broker (competitive auction, commission) or direct to providers (no commission, no auction) — the channel economics are compared in broker vs. provider. Typical qualifying profile: insured 65+, face $100,000+, health decline since issue; typical proceeds 10–35% of face.

Two calibrations keep the memo honest. Offers are not guaranteed — healthy insureds with premium-heavy policies frequently draw none, and the drivers are explained in how settlement value is calculated. And the comparison must be after-tax and after-purpose: a smaller certain sum now, invested by the trust, versus a larger uncertain sum later, for beneficiaries whose needs the trustee is charged to weigh.

Transaction Mechanics When a Trust Is the Seller

The transaction runs 60 to 120 days, and trust sellers add friction at predictable points counsel can pre-empt:

• Documentation package. Providers will require the full trust instrument (or a certification where state law permits), trustee acceptance and incumbency evidence, and any amendments. Assemble this before marketing, not at closing.
• Signatures. The trustee signs as owner; the insured (typically the grantor) signs HIPAA authorizations and insured-specific disclosures. Both must cooperate — a grantor who refuses medical releases stops the transaction, which is worth confirming before engagement letters go out.
• Underwriting. Medical records retrieval and two independent life expectancy reports consume two to six weeks; nothing counsel does accelerates carriers and copy services, so calendar accordingly.
• Offer management. Require the broker to present every offer in writing with full compensation disclosure — most state statutes mandate this, and the file needs it regardless.
• Closing and escrow. Purchase price funds into independent escrow; the carrier processes change of ownership and beneficiary to the provider; escrow releases to the trust on confirmation. Verify proceeds are payable to the trust exactly as titled.
• Rescission. State law gives the seller 15 to 30 days to unwind; calendar the deadline and instruct the trustee not to commit proceeds until it passes.
• Post-closing. The provider will periodically verify the insured’s status for life — grantors should hear this from counsel, not from the first tracking letter.

Counsel should also gate the transaction on benefit interactions where the grantor’s own circumstances matter — an insured heading toward Medicaid has issues covered in life settlements and Medicaid spend-down — though with trust-owned policies the proceeds belong to the trust, which changes and often simplifies that analysis.

Tax Characterization for the Trust Seller

The income tax framework is Revenue Ruling 2009-13 as modified by the TCJA: proceeds are tax-free up to the seller’s basis (aggregate premiums paid, with no post-TCJA reduction for cost of insurance), ordinary income from basis to cash surrender value, and capital gain above CSV. The trust-specific overlay is where counsel earns the fee:

• Grantor trusts. Most funded ILITs are grantor trusts during the insured’s life, so the sale’s income lands on the grantor’s personal return while the cash stays in trust — a mismatch the grantor must anticipate and, depending on the instrument’s reimbursement provisions and state law, may or may not be able to soften.
• Non-grantor trusts. Compressed trust brackets reach the top federal rate quickly; the trustee should model whether distributions carrying out distributable net income in the sale year produce a better aggregate result, coordinating with beneficiaries’ own brackets.
• Basis reconstruction. Decades of premium history, sometimes across exchanged policies, must be assembled; order the carrier’s premium ledger at engagement.
• Information reporting. The TCJA’s reportable policy sale regime produces Form 1099-LS from the acquirer and Form 1099-SB from the carrier, so the IRS match is automatic and the fiduciary return must reconcile.
• Transfer tax hygiene. Sale proceeds are trust corpus. Routing them to the grantor without authority undoes the estate-exclusion architecture the ILIT existed to create; if the family wants the trust unwound, do it deliberately — termination, decanting, or agreed modification — with the transfer-tax consequences briefed.

The full computational framework, with worked examples counsel can hand the fiduciary’s accountant, is in the life settlement tax treatment guide; the ruling’s history and the TCJA basis fix are covered in Revenue Ruling 2009-13 explained.

After the Sale: What Becomes of the Trust

A policy sale converts the ILIT from an insurance-holding vehicle into a funded investment trust, and counsel should treat the trust’s future as part of the same engagement rather than an afterthought. The main paths:

• Continue as an investment trust. The instrument’s dispositive terms usually operate independently of the policy; proceeds are invested under the prudent investor standard and administered per the distribution provisions. Check whether the trust’s administrative provisions — drafted for an entity that held one asset and filed no meaningful returns — still fit an actively invested portfolio.
• Distribute and terminate. Where the instrument permits or beneficiaries and state law allow early termination, winding up may serve a family better than perpetuating a small trust with ongoing fiduciary and tax costs.
• Decant or modify. Proceeds can be decanted to a trust with modern administrative machinery, special needs provisions for a disabled beneficiary, or different dispositive terms where state decanting statutes permit.
• Redeploy into new coverage. Occasionally the right answer is different insurance — a guaranteed product, or hybrid long-term care coverage — purchased by the trust with sale proceeds, where the insured remains insurable and the protection purpose survives.

Close the engagement with the protective file assembled: instrument and authority analysis, in-force illustrations, the alternatives memo with market evidence, beneficiary notices or consents, intermediary licenses and compensation disclosures, all offers received, the tax memo, closing statement, rescission calendar, and the trustee’s final reasoned decision. That file is the difference between a fiduciary who made a judgment and a fiduciary who took a risk. For the broader estate-practice context in which these engagements arise, see life settlements for estate planning attorneys.

---

Frequently Asked Questions

What should an ILIT trustee do when the grantor stops paying premiums?

Treat it as an investment decision on a deadline, not an administrative hiccup. Order in-force illustrations to establish how long the policy survives without new money, then assemble the option set: renewed funding, reduced face amount, 1035 exchange, surrender, lapse, or a life settlement market test. For policies meeting the settlement profile — insured 65+, face $100,000+, health decline since issue — solicit offers through licensed intermediaries before choosing. Document the comparison and the decision. The grace period is only 30–31 days once premiums actually stop, so start early.

Can an ILIT trustee be held liable for surrendering a policy instead of selling it?

Yes, that is the emerging claim pattern. If a trust-owned policy would have drawn secondary-market offers several times its surrender value — the GAO found multiples of four to eight times are typical — beneficiaries can argue the trustee breached the prudent investor duty by realizing the lower figure without testing the market. The defense is process: a documented screen, actual offers solicited where the policy qualified, a written comparison of alternatives, and beneficiary notice. A surrender after a market test that produced no better offers is entirely defensible.

Does the trust instrument need specific language authorizing a life settlement?

Usually not — general powers to sell trust property cover a policy sale in most instruments. But older ILITs occasionally recite powers narrowly around holding and maintaining insurance, and any ambiguity deserves resolution before marketing: a nonjudicial settlement agreement, beneficiary consent, judicial instruction, or decanting to a modern instrument. Going forward, trust counsel should draft express authority to sell policies to licensed settlement providers, confirm no duty to maintain coverage beyond available trust funds, and add exculpation for good-faith disposition decisions made after a documented market test.

Who pays the income tax when an ILIT sells its policy?

It depends on grantor trust status. Most ILITs are grantor trusts during the insured’s life, so the Revenue Ruling 2009-13 tiers — ordinary income from basis to cash surrender value, capital gain above — land on the grantor’s personal return even though proceeds stay in the trust, creating a cash-flow mismatch to plan for. A non-grantor trust pays at compressed trust brackets, making sale-year distribution planning valuable. Either way, Forms 1099-LS and 1099-SB report the transaction, and the trust’s premium history must be assembled to establish basis.

Should beneficiaries consent before an ILIT policy is sold?

Consent is rarely legally required if the trustee holds power of sale, but it is the cheapest liability protection available. Beneficiaries who received notice of the policy’s trajectory, saw the market offers and the alternatives comparison, and signed a consent or nonjudicial settlement agreement almost never become plaintiffs — and a court reviewing the trustee’s conduct will weigh the transparency heavily. At minimum, give written notice with the substance of the analysis. Where a trustee is also a beneficiary, independent consent or a special trustee for the transaction cleans the conflict.

How long does it take for a trust to sell a life insurance policy?

Plan on 60 to 120 days from application to funded escrow, plus the state rescission window of 15 to 30 days before finality. The long poles are medical records retrieval and the two independent life expectancy reports (two to six weeks). Trust sellers add document diligence: providers require the full instrument or certification, trustee incumbency evidence, and precise conformity between the signing trustee and the owner of record. Assembling the trust package before marketing, and confirming the insured grantor will sign HIPAA releases, prevents the common delays.

What happens to an ILIT after its only policy is sold?

The trust continues as a funded investment trust unless deliberately wound up. Proceeds are corpus, invested under the prudent investor standard and administered per the existing dispositive terms. Families then choose among continuing (check that administrative provisions fit an invested portfolio), terminating early where the instrument or state law permits, decanting to a modernized trust, or purchasing replacement coverage if a protection need survives and the insured is insurable. What the trustee must not do is casually route proceeds back to the grantor — that unwinds the transfer-tax separation the ILIT was built to create.

Can a trust sell a survivorship policy while both insureds are alive?

Yes, though marketability is limited while both insureds are healthy, because the buyer’s payoff waits for the second death. Offers improve materially after the first death or when either insured’s health declines significantly. For trustees, this argues for repeated screening rather than one-time conclusions: a survivorship policy that drew no offers in 2022 may price well after a health event or first death. Since so much survivorship coverage was bought for estate-tax exposure the current $13M+ exemption eliminated, these policies are among the most common ILIT disposition candidates.

Related Reading

• Ilit Trustee Duties Guide
• Life Settlements For Trustees
• Life Settlements Estate Planning Attorneys
• Life Settlement Tax Treatment Guide

---

Pine Lake Life Solutions does not purchase life insurance policies and does not provide legal, tax, or investment advice. Information provided is for educational purposes only. Eligibility for any option, including life settlements, is not guaranteed and depends on individual circumstances, policy terms, underwriting, and market conditions. Consult independent legal, tax, or financial professionals before making decisions regarding a life insurance policy.